Results 191 to 200 of about 358,425 (341)

Supplementary Videos from Contact-Dependent Killing by Cytotoxic T Lymphocytes Is Insufficient for EL4 Tumor Regression <i>In Vivo</i>

, 2023
Richard J. Beck, Maarten Slagter, Joost B. Beltman   +2 more
openalex   +1 more source

CDK4/6 Inhibition Induces CD8+ T Cell Antitumor Immunity via MIF‐Induced Functional Orchestration of Tumor‐Associated Macrophages

Advanced Science, EarlyView.
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He, Yuzhong Peng, Lat‐lun Leong, Jingbo Zhou, Dongyang Tang, Weilu Wang, Xiaoran Wu, Josh haipeng Lei, Yongqin Ye, Yangyang Feng, Yunfeng Qiao, Xiangpeng Chu, Di Mu, Qi Zhao, Tzuming Liu, Yan Chen, Paul Kwonghang Tam, Chu‐Xia Deng   +17 more
wiley   +1 more source

HLA-DR expression in cytotoxic T lymphocytes: a key to boost the therapeutic potential of T cell-based strategies for breast cancer. [PDF]

Front Immunol
Salvador R, Correia BF, Grosa D, Martins T, Soares Baal SC, Saraiva DP, Cristóvão-Ferreira S, Pereira IL, Rebelo de Almeida C, Fior R, Jacinto A, Mathias C, Braga S, Cabral MG.   +13 more
europepmc   +1 more source

Fueling sentinel node via reshaping cytotoxic T lymphocytes with a flex-patch for post-operative immuno-adjuvant therapy. [PDF]

Nat Commun, 2023
Li B, Wang G, Miao K, Zhang A, Sun L, Yu X, Lei JH, Xie L, Yan J, Li W, Deng CX, Dai Y.   +11 more
europepmc   +1 more source

Allostimulation of patients' lymphocytes generates both T and NK-like cells cytotoxic for autologous melanoma

, 1985
Andrea Balsari, G Fossati, Donatella Taramelli, Gabriella Tona, D Delia, R Giardini, Giorgio Parmiani   +6 more
openalex   +2 more sources

Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome

Advanced Science, EarlyView.
Pharmacological SUMOylation inhibition (SUMOi) counteracts tumor immune evasion by unmasking an immunogenic HLA‐I peptide and neoepitope repertoire. By restoring HLA‐I ligand availability through increased antigen processing and presentation, enhanced proteasomal cleavage, and modulated TAP1 peptide affinity, SUMOi boosts tumor immunogenicity ...
Uta M. Demel, Anna Meurer, Badeel Kh. Q. Zaghla, Bilge Atay, Daniel Steiert, Luca V. Hummel, Konstandina Isaakidis, Chuanbing Zang, Michael Korenkov, Marlon Schielin, Schayan Yousefian, Shima Mecklenbräuker, Marieluise Kirchner, Simon Haas, Antonia Busse, Philipp Mertins, Stefan Müller, Matthias Wirth, Martin G. Klatt, Ulrich Keller   +19 more
wiley   +1 more source

A novel CTLA-4 blocking strategy based on nanobody enhances the activity of dendritic cell vaccine-stimulated antitumor cytotoxic T lymphocytes. [PDF]

Cell Death Dis, 2023
Yang W, Pang Y, Wang X, Lai Z, Lu Y, Zheng S, Wang W.   +6 more
europepmc   +1 more source

Cross-Reactions between the Cytotoxic T-Lymphocyte Responses of Human Immunodeficiency Virus-Infected African and European Patients [PDF]

, 1998
Deniz Duralı, Jacques Morvan, Franck Letourneur, D Schmitt, Nelly Guegan, Marc Dalod, Sentob Saragosti, Didier Sicard, J P Lévy, E Gomard   +9 more
openalex   +1 more source

rWTC‐MBTA Vaccine, Alone and Enhanced with Anti‐PD1, Elicits Immune Responses against CNS and Peripheral B‐Cell Lymphoma

Advanced Science, EarlyView.
An autologous whole‐tumor‐cell vaccine (rWTC‐MBTA) is evaluated in murine CNS lymphoma. Subcutaneous vaccination activates dendritic cells, broadens T‐cell priming, and drives lymphocyte trafficking to brain tumors, producing durable tumor control. Longitudinal bioluminescence and adoptive‐transfer assays verify CNS engagement. Combination with anti‐PD‐
Yaping Zhang, Juan Ye, Mitchell Sun, Samik Chakraborty, Alex Valenzuela, Shuran Chen, Qingfeng Xue, Wenyu Shi, Karel Pacak, Herui Wang, Zhengping Zhuang   +10 more
wiley   +1 more source

Clonally expanded effector CD4⁺ cytotoxic T lymphocytes are associated with severe neurological adverse events after immune checkpoint inhibitor therapy. [PDF]

J Immunother Cancer
Giguelay AM, Maschmeyer P, Müller-Jensen L, Schinke C, Maierhof SK, Nambiar N, Meyer M, Huehnchen P, Boehmerle W, Endres M, Knauss S, Ludwig LS.   +11 more
europepmc   +1 more source